ED
CAVM

Exane Derivatives’s Cavium, Inc. CAVM Stock Holding History

Exane Derivatives’s Portfolio CAVM Stock Details CAVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-201
Closed -$12.3K – 593
2015
Q3 		$12.3K Sell
201
-1,026
-84% -$68.4K ﹤0.01% 335
2015
Q2 		$84.4K Buy
+1,227
New +$86K 0.01% 261

Other funds holding CAVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
abrdn Investment Management Edinburgh, United Kingdom $29.6B AUM 25.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Exane Derivatives's CAVM Position: Q4 2015 in Review

Exane Derivatives sold out of Cavium, Inc. (CAVM) in Q4 2015, closing a stake of 201 shares — an estimated $12.3K sold.

Exane Derivatives first reported a position in CAVM in Q2 2015 and held it in 2 quarters. The position peaked at $84.4K in Q2 2015. 232 funds tracked by Wall St. Rank hold CAVM as of Q4 2015.

  • Exane Derivatives reported no remaining Cavium, Inc. position as of Q4 2015 after selling out during the quarter.
  • Exane Derivatives sold 201 Cavium, Inc. shares in Q4 2015, an estimated $12.3K.
  • Exane Derivatives first reported a position in Cavium, Inc. in Q2 2015 and held it in 2 quarters.
  • Exane Derivatives's Cavium, Inc. position peaked at $84.4K in Q2 2015.
  • 232 funds tracked by Wall St. Rank held Cavium, Inc. as of Q4 2015.

Based on Exane Derivatives's 13F filing for Q4 2015, filed 11 Feb 2016.